Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase II Supportive care Closed any age RPMI-DS-8815 NCI-V88-0552

Objectives

I.  Assess the pain relief produced by celiac axis nerve block, and 
hypnotherapy in patients with pancreatic cancer in whom oral analgesia is no 
longer satisfactory.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients of any age with advanced 
pancreatic cancer who are receiving oral or rectal narcotics and in whom 
intravenous narcotics have been recently initiated.  An estimated survival of 
at least 2 weeks is required.  Patients must be candidates for general 
anesthesia in the prone position and must be able to tolerate insertion of a 
vascular axis line under local anesthesia.

Expected Enrollment

35 patients per arm will be accrued.  The study is expected to require 7 years 
to complete.

Outline

Nonrandomized study.  No comparison is planned or intended among the arms.  
Treatment assignment is based on patient acceptance.
Arm I:  Pain Control.  Celiac block.
Arm II:  Pain Control.  Hypnotherapy.

Trial Contact Information

Trial Lead Organizations

Roswell Park Cancer Institute

Harold Douglass, MD, FACS, Protocol chair(Contact information may not be current)		Ph: 716-845-5738; 800-685-6825 Email: harold.douglass@roswellpark.org